Dupilumab improves pruritus and skin lesions in patients with prurigo nodularis: Pooled results from 2 phase 3 trials (LIBERTY-PN PRIME and PRIME2)Capsule Summary

• Egile Nagusiak: Gil Yosipovitch, MD (Egilea), Brian S. Kim, MD (Egilea), Shawn G. Kwatra, MD (Egilea), Nicholas K. Mollanazar, MD (Egilea), Sonja Ständer, MD (Egilea), Takahiro Satoh, MD, PhD (Egilea), Pedro Mendes-Bastos, MD (Egilea), Tsen-Fang Tsai, MD (Egilea), Elizabeth Laws, PhD (Egilea), Michael C. Nivens, PhD (Egilea), Jennifer Maloney, MD (Egilea), Genming Shi, PhD (Egilea), Ashish Bansal, MD, MBA (Egilea), Ariane Dubost-Brama, MD (Egilea)
• Formatua: Liburua
• Argitaratua: Elsevier, 2024-09-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Background: Phase 3 PRIME/PRIME2 trials independently demonstrated efficacy and an acceptable safety profile of dupilumab adults with moderate-to-severe prurigo nodularis. Objective: To obtain a more precise estimate of onset and magnitude of treatment effect using PRIME/PRIME2 pooled data. Methods:...